Differential expression of EphA5 protein in gastric carcinoma and its clinical significance.
Ki-67
ephrin type-A receptor 5
gastric cancer
human epidermal growth factor receptor 2
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
03
11
2017
accepted:
12
12
2018
entrez:
13
6
2019
pubmed:
13
6
2019
medline:
13
6
2019
Statut:
ppublish
Résumé
The aim of the present study was to evaluate ephrin type-A receptor 5 (EphA5) expression and its clinicopathological significance in gastric cancer. Gastric cancer tissues were analyzed by immunohistochemistry. The association between EphA5 expression and clinicopathological parameters, human epidermal growth factor receptor 2 (HER2) status and Ki-67 proliferation index was statistically analyzed. EphA5 expression was detected in all non-tumor gastric epithelia but was differentially expressed among gastric cancer samples. EphA5 was negatively expressed in 30/110 (27.3%) and positively expressed in 80/110 (72.3%) samples from patients with gastric cancer. EphA5 expression was significantly associated with Lauren classification (P=0.032), lymph node metastasis (P<0.001), HER2 expression (P=0.020) and Ki-67 expression (P=0.005). No significant association was determined between EphA5 expression and age, sex, primary location, depth of invasion and Tumor-Node-Metastasis stage. The present data indicated that EphA5 is differentially expressed in gastric cancer. EphA5 may therefore be a potential therapeutic target and may have clinical utility as a marker for lymph node metastasis in gastric cancer.
Identifiants
pubmed: 31186729
doi: 10.3892/ol.2019.10167
pii: OL-0-0-10167
pmc: PMC6507474
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5147-5153Références
Oncogene. 2005 Aug 25;24(36):5637-47
pubmed: 16007213
Oncogene. 2007 Jun 21;26(29):4243-52
pubmed: 17260020
Eur J Neurosci. 2007 Feb;25(3):744-52
pubmed: 17328773
Neurosci Bull. 2007 Sep;23(5):249-55
pubmed: 17952132
Histopathology. 2008 Jun;52(7):797-805
pubmed: 18422971
J Comp Neurol. 2009 Jun 1;514(4):310-28
pubmed: 19326470
Hum Pathol. 2010 Jan;41(1):48-58
pubmed: 19733895
Anticancer Res. 2010 Apr;30(4):1287-92
pubmed: 20530441
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Int J Cancer. 2012 Jun 15;130(12):2845-56
pubmed: 21780108
Gastric Cancer. 2013 Apr;16(2):261-7
pubmed: 22797858
Gut. 2013 Aug;62(8):1230-1
pubmed: 23426894
Int J Clin Exp Pathol. 2013 Dec 15;7(1):313-21
pubmed: 24427352
Oncol Lett. 2014 Jul;8(1):41-46
pubmed: 24959216
Breast Cancer. 2016 Mar;23(2):224-30
pubmed: 25082658
Oncol Rep. 2014 Dec;32(6):2657-65
pubmed: 25231727
BMC Cancer. 2015 Jan 22;15:18
pubmed: 25609195
J Biol Chem. 2015 Mar 20;290(12):7345-59
pubmed: 25623065
Br J Haematol. 2016 Apr;173(1):161-5
pubmed: 26105212
FASEB J. 2015 Oct;29(10):4268-72
pubmed: 26116706
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Cancer Res. 2016 Apr 1;76(7):1825-36
pubmed: 26833123
Clin Lab. 2016;62(1-2):141-53
pubmed: 27012044
Histol Histopathol. 2017 May;32(5):491-497
pubmed: 27651378
Ann Oncol. 2017 Jan 1;28(1):110-115
pubmed: 27687309
J Ovarian Res. 2016 Nov 25;9(1):83
pubmed: 27887627
Pathology. 2017 Jan;49(1):38-43
pubmed: 27931719
Eur Surg Res. 2017;58(3-4):158-168
pubmed: 28273657
Oncol Res. 2018 Sep 14;26(8):1295-1305
pubmed: 29402343
Hum Pathol. 2018 Oct;80:82-86
pubmed: 29530751
Gene. 2018 Oct 5;673:102-106
pubmed: 29908284
Cancer Res. 1995 Nov 15;55(22):5400-7
pubmed: 7585609
J Neurosci Res. 1994 Jan;37(1):129-43
pubmed: 8145300
Cell. 1997 Aug 8;90(3):403-4
pubmed: 9267020